GAP mimetic activity of pan-Ras TCI daraxonrasib synergizes with K-Ras Switch-II pocket inhibition

This study demonstrates that the pan-Ras tricomplex inhibitor daraxonrasib acts as a pharmacologic GAP mimetic to restore GTPase activity, thereby synergizing with Switch-II pocket inhibitors like adagrasib to enhance K-Ras engagement, accelerate pathway suppression, and improve therapeutic efficacy in mutant cell lines.

The Gist

The Big Picture: Stopping a Stuck Light Switch

Imagine your cells are a giant house full of light switches. These switches control everything from how you grow to how you repair damage. One specific type of switch, called Ras, is supposed to be very smart: it turns ON when it needs to send a signal, and then it automatically turns OFF when the job is done.

However, in many cancers, the Ras switch gets broken. It gets stuck in the ON position. Because it never turns off, it screams "GROW!" and "DIVIDE!" constantly, leading to a tumor.

For a long time, scientists have tried two main ways to fix this broken switch:

1. The "Off" Button (Switch-II Inhibitors): These drugs wait for the broken switch to naturally reset to "OFF" (which happens very rarely for the broken ones) and then lock it there so it can't turn back on.
2. The "Jammer" (Tricomplex Inhibitors): These drugs grab the switch while it's screaming "ON" and physically block it from talking to the rest of the house.

This paper introduces a brilliant new strategy: What if we use the "Jammer" to force the broken switch to turn "OFF," and then immediately lock it down with the "Off Button"?

---

The Characters in Our Story

1. The Broken Switch (Mutant Ras): The villain. It's stuck in the "ON" state (GTP-bound) and won't stop growing.
2. The "Off Button" Drug (Adagrasib/HRS-4642): A drug that only works when the switch is in the "OFF" state (GDP-bound). It's great, but it has a problem: the broken Ras switch stays "ON" so long that the drug rarely gets a chance to grab it.
3. The "Jammer" Drug (Daraxonrasib): A new drug that grabs the switch while it's "ON." It recruits a helper protein (Cyclophilin A) to form a three-person team (a "Tricomplex").
4. The Magic Trick: Scientists discovered that when Daraxonrasib grabs the switch, it doesn't just block it; it actually tricks the broken switch into turning itself OFF. It acts like a "GAP Mimetic" (a fake helper that forces the switch to reset).

The Analogy: The Jammed Door and the Security Guard

Imagine a door (the Ras protein) that is stuck wide open, letting a flood of water (cancer signals) into the house.

• The Old Way: You try to put a heavy lock on the door (Adagrasib), but the door is stuck open so tightly that you can't get the lock to fit. You have to wait for the door to wiggle shut on its own, which takes forever.
• The New Way (This Paper): You bring in a special tool (Daraxonrasib). This tool grabs the door while it's open and forces it to slam shut.
• The Synergy: The moment the tool forces the door shut, you immediately slam the heavy lock on it (Adagrasib). Because the tool forced the door to close, the lock fits perfectly and instantly.

The Result: The door is locked shut much faster and much tighter than if you tried to do it alone.

What the Scientists Found

The researchers tested this idea in two ways:

1. In the Lab (Test Tubes): They took the broken Ras protein and tried to lock it with the "Off Button" drug. It was slow. But when they added the "Jammer" drug first, the protein turned "OFF" rapidly, and the lock clicked into place almost instantly.
2. In the Cells (Living Cancer): They treated cancer cells with the drugs.
   • Alone: The drugs worked, but slowly.
   • Together: The combination worked like a rocket. The cancer signals (p-ERK) shut down much faster, and the cancer cells died much more effectively.

They tested this on two different types of broken switches (G12C and G12D mutations) and found that the "One-Two Punch" worked for both.

Why This Matters

• Supercharging Old Drugs: We already have drugs like Adagrasib that are approved to treat cancer. This paper shows that adding the new "Jammer" drug makes the old drugs work much better.
• Lower Doses: Because the drugs work so well together, doctors might be able to use smaller doses of each. This is huge because it could mean fewer side effects for patients.
• Beating Resistance: Cancer is tricky; it often learns how to dodge a single drug. By hitting the switch from two different angles at once (forcing it off, then locking it), it becomes much harder for the cancer to fight back.

The Bottom Line

This paper is like discovering that two keys work better together than apart. One key (Daraxonrasib) forces the broken cancer switch to turn off, and the other key (Adagrasib) locks it in that off position. Together, they are a powerful team that could lead to better, safer cancer treatments.

Technical Summary

1. Problem Statement

• The Challenge of Ras Mutations: Oncogenic mutations in K-Ras (particularly G12C, G12D, and G12V) are major drivers of cancer. These mutations impair the intrinsic GTPase activity of Ras and its ability to interact with GTPase-activating proteins (GAPs), locking the protein in a constitutively active "ON" (GTP-bound) state.
• Limitations of Current Therapies:
  • Switch-II (SW-II) Inhibitors: Drugs like adagrasib (G12C) and HRS-4642 (G12D) target the GDP-bound "OFF" state. Their efficacy is kinetically constrained because mutant Ras spends very little time in the GDP state due to slow endogenous hydrolysis.
  • Pan-Ras Tricomplex Inhibitors (TCIs): Drugs like daraxonrasib (RMC-6236) target the GTP-bound "ON" state by recruiting Cyclophilin A (CypA). While they block effector binding, their ability to restore GTPase activity in mutants was a recent, surprising discovery that required mechanistic validation.
• The Gap: There is a need to understand the structural mechanism by which TCIs restore GTPase activity and to determine if combining a GTP-state inhibitor (TCI) with a GDP-state inhibitor (SW-II) creates a synergistic therapeutic effect to overcome resistance and toxicity.

2. Methodology

The study employed a multi-disciplinary approach combining structural biology, biochemistry, and cell biology:

• Structural Analysis: The authors analyzed the crystal structure of a pan-Ras TCI (specifically the analog RMC-7977) bound to K-Ras(GDP-AlF₃) and CypA. This transition-state mimic was compared against known endogenous GTPase-GAP complexes (e.g., Ras-RasGAP, Ran-RanGAP) to identify mechanistic parallels.
• In Vitro Kinetic Assays: Recombinant K-Ras G12C protein was loaded with GTP or GDP. Covalent labeling by the SW-II inhibitor adagrasib was monitored via Liquid Chromatography/Mass Spectrometry (LC/MS) in the presence and absence of daraxonrasib and CypA.
• Cellular Engagement Studies: MIAPaCa-2 cells (KRAS G12C) were treated with adagrasib alone or in combination with daraxonrasib. Target engagement was measured over time via Western blot mass-shift assays. Downstream signaling (p-ERK) was also monitored.
• Synergy Viability Assays: H358 (KRAS G12C) and AsPC-1 (KRAS G12D) cell lines were treated with varying concentrations of SW-II inhibitors (adagrasib or HRS-4642) and daraxonrasib. Cell viability was measured after 120 hours, and synergy was calculated using the Loewe synergy model.

3. Key Contributions

• Mechanistic Insight (GAP Mimicry): The paper establishes that daraxonrasib acts as a pharmacologic GAP mimetic. Structural analysis reveals that the ternary complex (Ras-CypA-TCI) induces a "closed" Switch-I conformation where Tyr32 and Gln61 are positioned to coordinate the catalytic water for nucleophilic attack on the $\gamma$-phosphate. This mimics non-arginine-finger GAPs (like RanGAP) rather than the classic Arg-finger mechanism of RasGAP.
• Synergistic Mechanism: The study demonstrates that by accelerating the hydrolysis of GTP to GDP, daraxonrasib rapidly enriches the mutant Ras population in the GDP state, thereby sensitizing it to covalent trapping by GDP-selective SW-II inhibitors.
• Validation Across Mutants: The synergy was validated for both G12C (using adagrasib) and G12D (using HRS-4642), suggesting a broad applicability across common Ras mutations.

4. Key Results

• Structural Parallels: The K-Ras(GDP-AlF₃)-CypA-daraxonrasib complex shows a transition-state arrangement strikingly similar to the Ran-RanGAP complex. Key features include the closed Switch-I conformation and the positioning of Tyr32 near the $\gamma$-phosphate, facilitating GTP hydrolysis without an Arg-finger.
• Accelerated Target Engagement (In Vitro & In Cellulo):
  • In Vitro: Adagrasib alone labeled K-Ras(GTP) G12C very slowly. The addition of daraxonrasib and CypA significantly accelerated covalent labeling, confirming restored GTPase turnover.
  • In Cells: In MIAPaCa-2 cells, adagrasib alone took 120–240 minutes to fully engage K-Ras G12C. The combination with daraxonrasib reduced this time to ~60–90 minutes and resulted in rapid suppression of p-ERK signaling.
• Synergy Scores:
  • G12C (H358 cells): The combination of adagrasib and daraxonrasib yielded a maximum Loewe synergy score of ~20 at a 40:1 ratio.
  • G12D (AsPC-1 cells): The combination of HRS-4642 and daraxonrasib yielded an even higher synergy score of >30 at a 14:1 ratio. This correlates with the observation that G12D mutants exhibit even stronger GTPase restoration by daraxonrasib than G12C.
• Signaling Suppression: The combination therapy resulted in more rapid and profound suppression of p-ERK compared to monotherapies.

5. Significance and Implications

• Rational Combination Therapy: This work provides a strong rationale for combining "ON-state" inhibitors (TCIs) with "OFF-state" inhibitors (SW-II). This dual-state targeting creates a "kinetic trap" that overcomes the slow intrinsic hydrolysis of mutant Ras.
• Overcoming Resistance: The synergy suggests this combination could overcome resistance mechanisms such as mutant allele amplification or secondary mutations that increase the GTP-bound pool, which often limit the efficacy of single-agent SW-II inhibitors.
• Toxicity Mitigation: Because the combination is highly synergistic, it may allow for dose reductions of both agents. This is critical for mitigating on-target toxicities (e.g., hepatotoxicity with adagrasib, potential Ras-dependent toxicity with pan-Ras inhibitors) while maintaining efficacy.
• Future Drug Design: The identification of daraxonrasib as a GAP mimetic opens new avenues for structure-guided drug design. Future agents could be optimized specifically to enhance the "closed Switch-I" conformation to further boost GTPase activity, potentially even for mutants lacking Gln61.

In summary, the paper defines daraxonrasib not just as a binder of active Ras, but as a catalytic enhancer of Ras GTP hydrolysis. By converting the "ON" state to the "OFF" state more rapidly, it primes mutant Ras for efficient inhibition by existing and next-generation GDP-state drugs, offering a potent strategy to treat Ras-driven cancers.